The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma

被引:95
作者
Giannini, Riccardo
Ugolini, Clara
Lupi, Cristiana
Proietti, Agnese
Elisei, Rossella
Salvatore, Giuliana
Berti, Piero
Materazzi, Gabriele
Miccoli, Paolo
Santoro, Massimo
Basolo, Fulvio [1 ]
机构
[1] Univ Pisa, Dept Surg, I-56126 Pisa, Italy
[2] Univ Pisa, Dept Endocrinol, I-56126 Pisa, Italy
[3] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy
[4] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy
关键词
CANCER; RET/PTC; REARRANGEMENTS; INHIBITORS; NEOPLASIA; DIAGNOSIS;
D O I
10.1210/jc.2007-0594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Papillary thyroid carcinoma ( PTC) is frequently multifocal. Independent PTC foci may occur either from intraglandular metastases from a single dominant tumor or as unrelated neoplastic clones. In rare cases, the simultaneous presence of PTC foci of different histopathological subtypes points to independent sites of tumor formation. Objectives: We examined the pattern of BRAF mutations in non-contiguous tumor foci and node metastases from 69 patients affected by multicentric PTC. These included 19 cases characterized by the simultaneous presence of different PTC histopathological variants. Design: BRAF ( exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples. Results: Discordant patterns of BRAF mutation were found in about 40% of the multifocal PTCs. In node metastases, BRAF mutations were, in most but not all the cases, concordant with the dominant tumor. A discordant pattern of BRAF mutation was also found in about 50% of the cases in which multiple foci of different histopathological variants were present. Conclusions: The heterogeneous distribution of BRAF mutations suggests that discrete tumor foci in multifocal PTC may occur as independent tumors. This information has to be considered in the design of targeted therapeutic approaches with BRAF pathway inhibitors.
引用
收藏
页码:3511 / 3516
页数:6
相关论文
共 32 条
[1]   Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status [J].
Abrosimov, Alexander ;
Saenko, Vladimir ;
Rogounovitch, Tatiana ;
Namba, Hiroyuki ;
Lushnikov, Evgeny ;
Mitsutake, Norisato ;
Yamashita, Shunichi .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :196-200
[2]   Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas [J].
Adeniran, AJ ;
Zhu, ZW ;
Gandhi, M ;
Steward, DL ;
Fidler, JP ;
Giordano, TJ ;
Biddinger, PW ;
Nikiforov, YE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) :216-222
[3]  
Akslen LA, 2000, CANCER, V88, P1902, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1902::AID-CNCR20>3.0.CO
[4]  
2-Y
[5]  
CARCANGIU ML, 1985, CANCER-AM CANCER SOC, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO
[6]  
2-Z
[7]   Minireview: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis [J].
Ciampi, Raffaele ;
Nikiforov, Yuri E. .
ENDOCRINOLOGY, 2007, 148 (03) :936-941
[8]  
Dean D S, 2000, Cancer Control, V7, P229
[9]   Pathology and genetics of thyroid carcinoma [J].
Delellis, Ronald A. .
JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (08) :662-669
[10]   Significance of BRAF mutations in papillary thyroid carcinoma:: prognostic and therapeutic implications [J].
Groussin, L ;
Fagin, JA .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (04) :180-181